import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'hexarelin-cd36-cardiac-research-jun22-2026',
  title: 'Hexarelin and CD36: The Cardioprotective Research Profile of a Forgotten GHS',
  description:
    'Hexarelin is a synthetic hexapeptide studied for growth hormone secretagogue activity and — distinctly — cardioprotective effects mediated through CD36 receptor binding independent of GH secretion. This article reviews the published science.',
  category: 'Compound Profiles',
  readMinutes: 11,
  publishedAt: '2026-06-22',
  ogImage: '/og-image.jpg',
  body: [
    {
      type: 'callout',
      text: 'For research and educational purposes only. Hexarelin is a research peptide not approved for human therapeutic use. Nothing in this article constitutes medical advice.',
    },
    {
      type: 'paragraph',
      text: 'Hexarelin (sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) developed in the early 1990s. It acts as an agonist at the GHS-R1a receptor — the ghrelin receptor — and has been studied for GH-releasing effects, hypothalamic-pituitary axis interactions, and a range of cardioprotective properties that appear to be at least partially independent of GH secretion. It is this dual profile — GH secretagogue plus direct cardiac effects via CD36 — that makes Hexarelin one of the scientifically more interesting research peptides in cardiovascular pre-clinical research, despite receiving less mainstream attention than GHRP-2, GHRP-6, or Ipamorelin.',
    },
    {
      type: 'heading',
      text: 'GHS-R1a Agonism: GH-Secretagogue Profile',
    },
    {
      type: 'paragraph',
      text: 'Like other GHS compounds (Ipamorelin, GHRP-6, MK-677), Hexarelin binds and activates the GHS-R1a receptor expressed in the pituitary, hypothalamus, and peripheral tissues. GHS-R1a activation in the pituitary triggers GH release. In comparative studies, Hexarelin produces greater peak GH secretion than GHRP-6 and Ipamorelin in most rodent models. However, this potency advantage is partially offset by rapid desensitization — repeated Hexarelin administration leads to blunted GH response more quickly than with Ipamorelin. Co-administration with GHRH analogs produces synergistic GH release, as documented with other GHSs.',
    },
    {
      type: 'paragraph',
      text: 'Unlike Ipamorelin, Hexarelin is not selective for GH at higher doses — it stimulates cortisol and prolactin secretion in a dose-dependent manner. This is a relevant consideration for research protocols where hormonal specificity is required: Ipamorelin may be preferred when isolated GH-axis modulation is the research objective, while Hexarelin\'s broader receptor activity is appropriate when studying GHS effects on multiple pituitary hormones or cardiac tissue.',
    },
    {
      type: 'heading',
      text: 'CD36 Receptor Binding: The Cardioprotective Mechanism',
    },
    {
      type: 'paragraph',
      text: 'The critical distinguishing feature of Hexarelin research is its interaction with CD36 — a scavenger receptor expressed on cardiac myocytes, endothelial cells, and macrophages. CD36 has multiple biological roles: fatty acid uptake and utilization in cardiac tissue, oxidized LDL recognition (relevant to atherosclerosis research), and angiogenesis regulation. Hexarelin binds CD36 in cardiac tissue, and this binding is believed to mediate its cardioprotective effects independently of GH or IGF-1 elevation.',
    },
    {
      type: 'paragraph',
      text: 'This was established in GH-deficient animal models where cardioprotective effects persisted despite negligible GH response to Hexarelin administration — effectively dissociating the cardiac effects from the pituitary axis. The CD36 binding site for Hexarelin is distinct from the GHS-R1a binding site, and the two receptor systems appear to operate in parallel rather than in sequence.',
    },
    {
      type: 'heading',
      text: 'Ischemia-Reperfusion Injury Research',
    },
    {
      type: 'paragraph',
      text: 'Studies in isolated heart preparations and in vivo rodent models have documented that Hexarelin reduces ischemia-reperfusion (I/R) injury — the cell death and dysfunction that occurs when blood flow is restored after a period of ischemia. Locatelli et al. (1999) and subsequent work demonstrated that Hexarelin pre-treatment in rats reduced infarct size following coronary occlusion/reperfusion. Critically, these effects were present in hypophysectomized (GH-deficient) animals — confirming the mechanism is not GH-dependent — and were blocked by CD36 antagonism, confirming CD36 as the relevant mediator.',
    },
    {
      type: 'heading',
      text: 'Cardiac Function in GH Deficiency Models',
    },
    {
      type: 'paragraph',
      text: 'GH-deficient patients and animal models consistently show impaired cardiac function — reduced cardiac output, increased vascular resistance, and altered cardiac morphology. Hexarelin treatment in GH-deficient models has shown improved cardiac output and ejection fraction, reduction in left ventricular hypertrophy in some models, and improved ventricular contractility documented in isolated heart preparations. Some of these effects are mediated via GH/IGF-1 while others — particularly contractility effects — appear to involve direct cardiac receptor activation.',
    },
    {
      type: 'heading',
      text: 'Anti-Apoptotic and Anti-Fibrotic Activity',
    },
    {
      type: 'paragraph',
      text: 'Hexarelin treatment in cardiac research models has been associated with reduced cardiomyocyte apoptosis following ischemic stress, modulation of pro-apoptotic signaling (Bcl-2/Bax ratio changes), and in some models, attenuation of cardiac fibrosis following injury. These findings have led researchers to study Hexarelin as a potential probe compound for understanding CD36-mediated cardioprotection pathways, separate from its utility as a GH secretagogue.',
    },
    {
      type: 'heading',
      text: 'Desensitization: A Key Research Design Consideration',
    },
    {
      type: 'paragraph',
      text: 'Hexarelin\'s rapid GHS-R1a desensitization with continuous administration is a critical protocol design consideration. Research designs using Hexarelin for chronic GH elevation will encounter diminishing GH response within days of continuous dosing. This makes Hexarelin less suitable for long-duration GH-axis studies compared to Ipamorelin or CJC-1295 combinations, but does not impair its utility as a probe for acute GH release or for CD36-mediated cardiac effects, where pulsatile or acute dosing is more appropriate.',
    },
    {
      type: 'heading',
      text: 'How Hexarelin Compares to Other GHSs',
    },
    {
      type: 'list',
      items: [
        'Ipamorelin: High GH selectivity, minimal cortisol/prolactin stimulation, slower desensitization — preferred for chronic GH research',
        'GHRP-2: Moderate potency, some cortisol/prolactin activity, less CD36 binding documented',
        'GHRP-6: Potent appetite stimulation via ghrelin pathway; significant cortisol/prolactin; limited cardiac research',
        'Hexarelin: Highest potency for GH release among synthetic GHSs; rapid desensitization; unique CD36 cardiac activity',
        'MK-677: Oral bioavailability, very long half-life, sustained GH elevation — but no documented CD36 activity',
      ],
    },
    {
      type: 'heading',
      text: 'Sourcing Hexarelin for Research',
    },
    {
      type: 'paragraph',
      text: 'Hexarelin is a synthetic hexapeptide (MW: ~887 Da) and quality verification follows standard GHS procurement criteria: HPLC ≥98% purity with chromatogram, ESI-MS molecular weight confirmation, LAL endotoxin testing, and lyophilized form with cold-chain storage and shipping documentation. Given its potency and receptor selectivity profile, sequence confirmation is particularly important for Hexarelin — the D-amino acid substitution (D-2-methyltryptophan at position 2) is critical to its metabolic stability and receptor binding characteristics.',
    },
    {
      type: 'paragraph',
      text: 'Nexphoria supplies Hexarelin to qualified researchers with full third-party CoA documentation and cold-chain handling protocols consistent with our broader peptide quality standards.',
    },
  ],
};
